


NVP-BAW2881

Chemical Properties

CAS No. : 861875-60-7
 Formula: C₂₂H₁₅F₃N₄O₂
 Molecular Weight: 424.38
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

Description	NVP-BAW2881 (BAW2881) is a potent and selective VEGFR (vascular endothelial growth factor receptor tyrosine kinase) inhibitor with efficacy in inhibiting chronic and acute skin inflammation.
Targets(IC50)	Raf,Bcr-Abl,Tie-2,VEGFR
In vitro	In vitro experiments demonstrated that NVP-BAW2881 was able to inhibit the proliferation, migration, and tubulogenesis of human lymphatic endothelial cells and umbilical vein endothelial cells.
In vivo	In vitro experiments demonstrated that NVP-BAW2881 was able to inhibit the proliferation, migration, and tubulogenesis of human lymphatic endothelial cells and umbilical vein endothelial cells.
Cell Research	HUVECs or LECs (1.2×10 ³) were seeded into fibronectin-coated 96-well plates. After 24 hours, the cells were transferred into LEC medium containing 2% fetal bovine serum and incubated for an additional 24 hours. Cells(eight wells/condition) were incubated with medium alone(control), 20 ng/ml VEGF-A, or a combination of 20 ng/ml VEGF-A and 1 nmol/L to 1 mol/L NVP-BAW2881. Proliferation was also assayed in LECs incubated with 500 ng/ml VEGF-C. The dimethyl sulfoxide concentration was adjusted to 0.1% in all wells. After 72 hours, cells were incubated with 5-methylumbelliferylheptanoate for subsequent fluorescent quantification of viable cells, using a SpectraMax Gemini electron microscope. (Only for Reference)

Solubility Information

Solubility	H ₂ O: < 1 mg/mL (insoluble or slightly soluble), DMSO: 78 mg/mL (183.8 mM),Sonication is recommended. Ethanol: 16 mg/mL (37.7 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.71 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3564 mL	11.7819 mL	23.5638 mL
5 mM	0.4713 mL	2.3564 mL	4.7128 mL
10 mM	0.2356 mL	1.1782 mL	2.3564 mL
50 mM	0.0471 mL	0.2356 mL	0.4713 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Bold G, et al. J Med Chem. 2016,59(1):132-46.

Weidemann AK, et al. Clin Cosmet Investig Dermatol. 2013, 6:233-44.

Halin C, et al. Am J Pathol. 2008, 173(1):265-77.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481